Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience

AstraZeneca will redeploy resources through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.